Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Antipsychotic Augmentation With L-Dopa

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
George Foussias, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier:
NCT01636037
First received: July 5, 2012
Last updated: March 11, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2016
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)